IL6 and hematologic disorder: Additionally, accumulating evidence indicates that ATM drives the BM-mediated resistance to chemotherapy in other hematological malignancies, such as multiple myeloma and acute lymphoblastic leukemia via upregulation of cytokines such as IL-6 (Tang et al., 2018) or CCL3, CCL4, and GDF15 (Chen et al., 2019).